Breaking News

BARDA Awards $37.6M Leukine Supply Contract to Sanofi

Sanofi expects to submit a sBLA to the U.S. FDA next year for Acute Radiation Syndrome

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, has awarded Sanofi a $37.6 million contract to supply and manage inventory for Leukine. Sanofi Genzyme, the specialty care global business unit of Sanofi, is developing Leukine for the treatment of acute radiation syndrome, a serious illness that occurs in people exposed to high doses of radiation. The c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters